Mounjaro is most often covered alongside Eli Lilly, which appears in 2 of these 3 stories. Each story carries 9 original sources on average, compared with 3.3 for the broader beat in this window. Across a 54-day span, the pace is roughly 0.4 stories per week.
Coverage balanceBalanced directional read. Positive and negative coverage are within 0 percentage points.
33% positive
33% neutral
33% negative
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Mounjaro
Mounjaro is most often covered alongside Eli Lilly, which appears in 2 of these 3 stories. Each story carries 9 original sources on average, compared with 3.3 for the broader beat in this window. Across a 54-day span, the pace is roughly 0.4 stories per week. Their average consequence score of 7 runs above the beat's 6.2 for that window. Coverage clusters in clinical-trial, which accounts for 1 of those 3, with the remainder spread across 2 other categories. This profile follows 3 Biotech stories mentioning Mounjaro across the period from March 13, 2026 to May 5, 2026.
Stories tracked
3
Per week
0.4
Sources per story
9
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 203 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Mounjaro. Shared-story counts are live from our verified record — not editorial picks.
Eli Lilly's innovative drug pipeline, including treatments for obesity and diabetes, positions it as a leader in biotech, with stock gains of 25% year-to-date signaling strong potential. For biotech professionals, this highlights the impact of clinical successes on market value and future R&D investments. Regulatory contexts like FDA approvals could further accelerate Eli Lilly's dominance in gene therapy and personalized medicine.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.
Mounjaro is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
